Delayed
Nasdaq Stockholm
10:20:44 2024-05-21 am EDT
|
5-day change
|
1st Jan Change
|
348
SEK
|
+2.05%
|
|
+2.35%
|
-13.00%
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
5,174
|
4,619
|
4,528
|
3,860
|
-
|
-
|
Enterprise Value (EV)
1 |
5,174
|
4,912
|
4,825
|
4,008
|
3,860
|
3,695
|
P/E ratio
|
1,235
x
|
30.4
x
|
32.3
x
|
24.8
x
|
19.6
x
|
17.5
x
|
Yield
|
-
|
0.67%
|
0.75%
|
0.81%
|
1.02%
|
1.14%
|
Capitalization / Revenue
|
-
|
3.45
x
|
3.22
x
|
2.77
x
|
2.53
x
|
2.35
x
|
EV / Revenue
|
-
|
3.67
x
|
3.43
x
|
2.87
x
|
2.53
x
|
2.25
x
|
EV / EBITDA
|
-
|
18.9
x
|
18.5
x
|
14.4
x
|
12
x
|
10.5
x
|
EV / FCF
|
-
|
29.1
x
|
42.2
x
|
20.1
x
|
19.2
x
|
16.4
x
|
FCF Yield
|
-
|
3.44%
|
2.37%
|
4.96%
|
5.21%
|
6.12%
|
Price to Book
|
-
|
6.65
x
|
5.62
x
|
4.14
x
|
3.51
x
|
3.02
x
|
Nbr of stocks (in thousands)
|
11,321
|
11,321
|
11,321
|
11,321
|
-
|
-
|
Reference price
2 |
457.0
|
408.0
|
400.0
|
341.0
|
341.0
|
341.0
|
Announcement Date
|
2/24/22
|
2/22/23
|
2/20/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
1,339
|
1,408
|
1,395
|
1,526
|
1,645
|
EBITDA
1 |
-
|
260.6
|
261.3
|
278
|
321.9
|
352.6
|
EBIT
1 |
-
|
220
|
214.6
|
223.2
|
263.3
|
291.1
|
Operating Margin
|
-
|
16.43%
|
15.24%
|
15.99%
|
17.25%
|
17.69%
|
Earnings before Tax (EBT)
1 |
-
|
196.9
|
180.2
|
203
|
255
|
286
|
Net income
1 |
4.145
|
151.8
|
140.2
|
155.4
|
196.6
|
220.3
|
Net margin
|
-
|
11.33%
|
9.96%
|
11.14%
|
12.88%
|
13.39%
|
EPS
2 |
0.3700
|
13.40
|
12.39
|
13.73
|
17.37
|
19.46
|
Free Cash Flow
1 |
-
|
169
|
114.2
|
199
|
201
|
226
|
FCF margin
|
-
|
12.62%
|
8.11%
|
14.26%
|
13.17%
|
13.74%
|
FCF Conversion (EBITDA)
|
-
|
64.84%
|
43.71%
|
71.58%
|
62.43%
|
64.1%
|
FCF Conversion (Net income)
|
-
|
111.34%
|
81.46%
|
128.06%
|
102.24%
|
102.6%
|
Dividend per Share
2 |
-
|
2.750
|
3.000
|
2.745
|
3.473
|
3.891
|
Announcement Date
|
2/24/22
|
2/22/23
|
2/20/24
|
-
|
-
|
-
|
Fiscal Period: December |
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
350.7
|
326.4
|
340.1
|
358.8
|
353
|
354.7
|
341.9
|
357.6
|
344
|
344
|
350
|
EBITDA
1 |
73.37
|
67.25
|
57.8
|
68.17
|
71.34
|
73.75
|
48.07
|
75.6
|
67
|
69
|
66
|
EBIT
1 |
63.38
|
57.33
|
47.35
|
57.83
|
60.72
|
61.59
|
34.5
|
62.1
|
53
|
56
|
52
|
Operating Margin
|
18.07%
|
17.56%
|
13.92%
|
16.12%
|
17.2%
|
17.37%
|
10.09%
|
17.37%
|
15.41%
|
16.28%
|
14.86%
|
Earnings before Tax (EBT)
1 |
56.01
|
52.5
|
39.9
|
50.68
|
59.42
|
51.88
|
18.24
|
64.13
|
44
|
49
|
46
|
Net income
1 |
42.49
|
43.15
|
27.48
|
38.8
|
-
|
-
|
16.36
|
49.7
|
34
|
37
|
35
|
Net margin
|
12.12%
|
13.22%
|
8.08%
|
10.81%
|
-
|
-
|
4.78%
|
13.9%
|
9.88%
|
10.76%
|
10%
|
EPS
|
3.750
|
-
|
2.430
|
3.430
|
4.030
|
3.480
|
1.440
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
8/17/22
|
11/11/22
|
2/22/23
|
5/16/23
|
8/17/23
|
10/30/23
|
2/20/24
|
5/3/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
293
|
297
|
148
|
-
|
-
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
165
|
Leverage (Debt/EBITDA)
|
-
|
1.125
x
|
1.136
x
|
0.5324
x
|
-
|
-
|
Free Cash Flow
1 |
-
|
169
|
114
|
199
|
201
|
226
|
ROE (net income / shareholders' equity)
|
-
|
24.8%
|
18.7%
|
17.9%
|
19.3%
|
18.5%
|
ROA (Net income/ Total Assets)
|
-
|
9.72%
|
8.4%
|
8.93%
|
10.4%
|
10.5%
|
Assets
1 |
-
|
1,562
|
1,669
|
1,741
|
1,897
|
2,092
|
Book Value Per Share
2 |
-
|
61.30
|
71.20
|
82.40
|
97.10
|
113.0
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
27.2
|
21.6
|
22.1
|
36.5
|
39.9
|
Capex / Sales
|
-
|
2.03%
|
1.53%
|
1.58%
|
2.39%
|
2.43%
|
Announcement Date
|
2/24/22
|
2/22/23
|
2/20/24
|
-
|
-
|
-
|
|
1st Jan change
|
Capi.
|
---|
| -14.75% | 361M | | +15.62% | 9.1B | | +39.55% | 2.41B | | -11.97% | 1.06B | | +20.86% | 856M | | -6.57% | 775M | | +23.40% | 727M | | +21.51% | 702M | | -16.87% | 587M | | -5.67% | 571M |
Purification & Treatment Equipment
|